Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune diseases

By developing novel compound antagonists against TLR7, TLR8 and TLR9, the problem of lack of effective and safe oral drugs in existing treatment methods has been solved, and effective treatment of systemic lupus erythematosus and lupus nephritis has been achieved, with excellent antagonism activity and security.

CN114728959BActive Publication Date: 2024-11-12F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080078375.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-11-12
Filing Date
2020-11-10
Publication Date
2024-11-12
Estimated Expiration
2040-11-10

AI Technical Summary

Technical Problem

Existing treatments for systemic lupus erythematosus (SLE) and lupus nephritis lack effective and safe oral medications, especially for the TLR7, TLR8 and TLR9 pathways, and there is insufficient steroid-free and non-cytotoxic therapy.

Method used

A novel compound has been developed as an antagonist of TLR7, TLR8 and TLR9, which inhibits the activation of these receptors through oral pathways. It is used to treat systemic lupus erythematosus and lupus nephritis, with excellent antagonistic activity and good cytotoxicity and lysis. Sex and human microsomal stability, while low CYP inhibition.

Benefits of technology

This compound effectively inhibits the TLR7, TLR8 and TLR9 pathways, provides a potential treatment plan for systemic lupus erythematosus and lupus nephritis, has high safety and continuous improvement effects, and is suitable for most autoimmune and inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114728959B_ABST
    Figure CN114728959B_ABST
Patent Text Reader

Abstract

The present invention relates to compounds of formula (I), #imgabs0# wherein R 1 To R 3 As described herein, and pharmaceutically acceptable salts, enantiomers or diastereomers thereof, as well as compositions comprising the compounds and methods of using the compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to organic compounds that can be used for the treatment and / or prevention of mammals, and in particular to antagonists of TLR7 and / or TLR8 and / or TLR9 that can be used for the treatment of systemic lupus erythematosus or lupus nephritis. Technical Field

[0002] Autoimmune connective tissue disease (CTD) includes typical autoimmune syndromes, such as systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSjS), mixed connective tissue disease (MCTD), dermatomyositis / polymyositis (DM / PM), rheumatoid arthritis (RA) and systemic sclerosis (SSc). Except RA, there is no real effective and safe therapy for patients. SLE represents a typical CTD, with a prevalence of 20-150 / 100,000, and causes extensive inflammation and tissue damage in different organs, from common symptoms of skin and joints to kidney, lung or heart failure. Traditionally, SLE has been treated with nonspecific anti-inflammatory drugs or immunosuppressants. However, long-term use of immunosuppressive drugs, for example, corticosteroids are only partially effective, and are accompanied by unexpected toxicity and side effects. Belimumab is the only FDA-approved drug for lupus in the past 50 years, although it has only a modestly delayed efficacy in some SLE patients (Navarra, SV et al., Lancet 2011, 377, 721.). Other biologics, such as anti-CD20 mAbs, mAbs against specific cytokines or their soluble receptors, have failed in most clinical studies. Therefore, new therapies are needed that provide sustained improvement in a larger proportion of patient groups and are safer for long-term use in many autoimmune and autoinflammatory diseases.

[0003] Toll-like receptors (TLRs) are an important family of pattern recognition receptors (PRRs) that can trigger a wide range of immune responses in a variety of immune cells. Endosomal TLR 7, TLR8, and TLR9 are natural host defense sensors that can identify nucleic acids derived from viruses and bacteria; specifically, TLR7 / TLR8 and TLR9 recognize single-stranded RNA (ssRNA) and single-stranded CpG-DNA, respectively. However, the abnormal nucleic acid sensing of TRL7, TRL8, and TRL9 is considered to be a key node in a wide range of autoimmune and autoinflammatory diseases (Krieg, AM et al., Immunol. Rev. 2007, 220, 251. Jiménez-Dalmaroni, MJ et al., Autoimmun Rev. 2016, 15, 1. Chen, JQ et al., Clinical Reviews in Allergy & Immunology 2016, 50, 1.). Anti-RNA and anti-DNA antibodies are recognized diagnostic markers for SLE, and these antibodies can deliver both self-RNA and self-DNA to endosomes. Self-RNA complexes can be recognized by TLR7 and TLR8, while self-DNA complexes can trigger TLR9 activation. In fact, defective clearance of self-RNA and self-DNA from blood and / or tissues is evident in patients with SLE (systemic lupus erythematosus). TLR7 and TLR9 have been reported to be upregulated in SLE tissues and are associated with the chronicity and activity of lupus nephritis, respectively. In B cells of SLE patients, TLR7 expression is associated with the production of anti-RNP antibodies, while TLR9 expression is associated with IL-6 and anti-dsDNA antibody levels. Consistently, in a lupus mouse model, TLR7 is required for anti-RNA antibodies and TLR9 for anti-nucleosome antibodies. On the other hand, overexpression of TLR7 or human TLR8 in mice promotes autoimmunity and autoinflammation. In addition, activation of TLR8 is particularly conducive to the secretion of inflammatory cytokines by mDC / macrophages, the process of neutrophil extracellular trapping (NETosis), the induction of Th17 cells, and the suppression of Treg cells. In addition to the described role of TLR9 in promoting B cell autoantibody production, activation of TLR9 by self-DNA in pDCs also leads to the induction of type I IFN and other inflammatory cytokines. Considering these roles of TLR9 in both pDCs and B cells, both of which are key players in the pathogenesis of autoimmune diseases, and the abundance of self-DNA complexes that readily activate TLR9 in many patients with autoimmune diseases, it may have additional benefits to further block the self-DNA-mediated TLR9 pathway in addition to inhibiting the TLR7 and TLR8 pathways.In summary, TLR7, 8 and 9 pathways represent new therapeutic targets for the treatment of autoimmune and autoinflammatory diseases for which there are no effective steroid-free and non-cytotoxic oral drugs, and inhibition of all of these pathways very upstream may lead to satisfactory therapeutic effects. Therefore, we have invented oral compounds that target and inhibit TLR7, TLR8 and TLR9 for the treatment of autoimmune and autoinflammatory diseases. Summary of the invention

[0004] The present invention relates to novel compounds of formula (I) and formula (Ia),

[0005]

[0006] in

[0007] R 1 for

[0008]

[0009] Where R 4 C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogen, nitro or cyano; R 4a C 1-6 Alkyl or C 3-7 Cycloalkyl; R 5 , R 5a and R 5b are independently selected from H and deuterium; R 6 is H or halogen;

[0010] R 2 C 1-6 alkyl;

[0011] R 3 is an unsubstituted or substituted heterocyclic group, a heterocyclic amino group, a heterocyclic group C 1-6 Alkylamino or substituted C 1-6 Alkoxy;

[0012] or a pharmaceutically acceptable salt thereof.

[0013] Another object of the present invention relates to novel compounds of formula (I) or (Ia) or (Ib), their preparation, drugs based on the compounds of the present invention, their preparation and the use of compounds of formula (I) or (Ia) or (Ib) as TLR7 and / or TLR8 and / or TLR9 antagonists, and for the treatment or prevention of systemic lupus erythematosus or lupus nephritis. Compounds of formula (I) or (Ia) or (Ib) show excellent TLR7 and / or TLR8 and / or TLR9 antagonistic activity. In addition, compounds of formula (I) or (Ia) or (Ib) also show good hPBMC, cytotoxicity, solubility, human microsomal stability and SDPK distribution, as well as low CYP inhibition. DETAILED DESCRIPTION

[0014] definition

[0015] The term "C 1-6 "Alkyl" means a saturated, straight-chain or branched alkyl group containing 1 to 6, especially 1 to 4 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, etc. In particular, "C 1-6 "Alkyl" groups are methyl, ethyl and n-propyl.

[0016] The term "C 3-7 "Cycloalkyl" means a saturated carbocyclic ring containing 3 to 7 carbon atoms, especially 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc. In particular, "C 3-7 "Cycloalkyl" groups are cyclopropyl, cyclopentyl and cyclohexyl.

[0017] The terms "halogen" and "halo" are used interchangeably herein to refer to fluorine, chlorine, bromine or iodine.

[0018] The term "C 1-6 "Alkoxy" means C 1-6 Alkyl-O-.

[0019] The term "halopyrrolidinyl" refers to a pyrrolidinyl group substituted once, twice or three times with halogen. Examples of halopyrrolidinyl groups include, but are not limited to, difluoropyrrolidinyl and fluoropyrrolidinyl.

[0020] The term "heterocyclyl" or "heterocycle" refers to a monovalent saturated or partially unsaturated monocyclic or bicyclic ring system having 3 to 12 ring atoms, which contains 1 to 5 heteroatoms selected from N, O and S, and the remaining ring atoms are carbon. In specific embodiments, the heterocyclyl is a monovalent saturated monocyclic ring system of 4 to 7 ring atoms, which contains 1, 2 or 3 ring heteroatoms selected from N, O and S, and the remaining ring atoms are carbon. Examples of monocyclic saturated heterocyclyl are aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro-thienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, oxazepanyl. Examples of bicyclic saturated heterocycles are azabicyclo[3.2.1]octyl, quinuclidinyl, oxazabicyclo[3.2.1]octyl, azabicyclo[3.3.1]nonanyl, oxaza-bicyclo[3.3.1]nonanyl, azabicyclo[3.1.0]hexanyl, oxodiazaspiro[3.4]octanyl, acetyloxodiazaspiro[3.4]octanyl, thiazabicyclo[3.3.1]nonanyl, oxoazaspiro[2.4]heptanyl, oxoazaspiro[3.4]octanyl, oxoazabicyclo[3.1.0]hexanyl and dioxotetrahydropyrrolo[1,2-a]pyrazinyl. Examples of bicyclic heterocyclic groups include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl; 5,6,7,8-tetrahydro-1,6-naphthyridinyl; 5,6,7,8-tetrahydro-1,7-naphthyridinyl; 5,6,7,8-tetrahydro-2,6-naphthyridinyl; 5,6,7,8-tetrahydro-2,7-naphthyridinyl; isoindolyl; 1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridin-2-yl; 3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl. Examples of heterocyclic groups may be further substituted by C 1-6 Alkyl, C 3-7 Cycloalkyl, halogen, hydroxyl, amino C 1-6 Alkylcarbonyl, C 1-6 Alkylpyrrolidinylcarbonyloxy or C 1-6 Alkoxy substitution.

[0021] The term "heterocyclylamino" refers to heterocyclyl-NH-.

[0022] The term "heterocyclyl C 1-6 "Alkylamino" means a heterocyclic-C 1-6 Alkyl-NH-.

[0023] The term "pharmaceutically acceptable salts" refers to salts that are not biologically or otherwise undesirable. "Pharmaceutically acceptable salts" include both acid addition salts and base addition salts.

[0024] "Pharmaceutically acceptable acid addition salts" refer to those pharmaceutically acceptable salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and the like, and organic acids, which may be selected from aliphatic, alicyclic, aromatic, aromatic aliphatic, heterocyclic, carboxylic and sulfonic acid organic acids, such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, pamoic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid, and the like.

[0025] The term "pharmaceutical base addition salt" refers to those pharmaceutical salts formed with organic or inorganic bases. Examples of acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese and aluminum salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include primary, secondary and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines and basic ion exchange resins (such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, tromethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine and polyamine resins).

[0026] The term "pharmaceutically active metabolite" refers to a pharmacologically active product produced by the metabolism of a specific compound or its salt in the body. After entering the human body, most drugs are substrates for chemical reactions that may change their physical properties and biological effects. These metabolic transformations, which usually affect the polarity of the compounds of the present invention, change the way the drug is distributed in the body and excreted from the body. However, in some cases, drug metabolism is necessary for therapeutic effects.

[0027] The term "therapeutically effective amount" refers to an amount of a compound or molecule of the invention that, when administered to a subject, (i) treats or prevents a particular disease, condition or disorder, (ii) reduces, ameliorates or eliminates one or more symptoms of a particular disease, condition or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition or disorder as described herein. The therapeutically effective amount depends on the compound, the disease state being treated, the severity of the disease being treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary doctor and other factors.

[0028] The term "pharmaceutical composition" means a mixture or solution comprising a therapeutically effective amount of an active drug ingredient together with a pharmaceutically acceptable excipient for administration to a mammal (eg, a human) in need thereof.

[0029] Antagonists of TLR7 and / or TLR8 and / or TLR9

[0030] The present invention relates to (i), which is a compound of formula (I),

[0031]

[0032] in

[0033] R 1 for

[0034] Where R 4 C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogen, nitro or cyano; R 4a C 1-6 Alkyl or C 3-7 Cycloalkyl; R 5 , R 5a and R 5b are independently selected from H and deuterium; R 6 is H or halogen;

[0035] R 2 C 1-6 alkyl;

[0036] R 3 is an unsubstituted or substituted heterocyclic group, a heterocyclic amino group, a heterocyclic group C 1-6 Alkylamino or substituted C 1-6 Alkoxy;

[0037] or a pharmaceutically acceptable salt thereof.

[0038] A further embodiment of the present invention is (ii), which is a compound of formula (I) according to (i), wherein R 1 for Where R 4 is cyano, R 5 is H or deuterium.

[0039] A further embodiment of the present invention is (iii), which is a compound of formula (I) according to (i) or (ii), wherein R 3 For (amino C 1-6 alkylcarbonyl)-2,5-diazabicyclo[2.2.1]heptyl; (amino C 1-6 Alkylcarbonyl)piperazinyl; (C1-6 Alkoxypyrrolidinyl)amino; (C 1-6 Alkyl)2aminoC 1-6 Alkoxy; (C 1-6 (alkylpyrrolidinylcarbonyl)piperazinyl; (halopyrrolidinyl)amino; (hydroxypyrrolidinyl)C 1-6 Alkylamino; (morpholinyl)C 1-6 Alkylamino; 1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl; 3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridinyl; amino(C 1-6 alkyloxy)pyrrolidinyl; amino-1,4-oxazepanyl; aminohalogenated pyrrolidinyl; aminooxopyrrolidinyl or azetidinyl C 1-6 Alkoxy.

[0040] Another embodiment of the present invention is (iv), which is a compound of formula (Ia),

[0041]

[0042] in

[0043] R 1 for Where R 4 is cyano, R 5 is H or deuterium;

[0044] R 2 C 1-6 alkyl;

[0045] a) R 3a For (C 1-6 Alkyl)2AminoC 1-6 Alkoxy; (halopyrrolidinyl)amino; (hydroxypyrrolidinyl)C 1-6 Alkylamino; (morpholinyl)C 1-6 Alkylamino or amino-1,4-oxazepanyl;

[0046] R 3b is H; or

[0047] b) R 3a is H;

[0048] R 3b For (amino C 1-6 alkylcarbonyl)-2,5-diazabicyclo[2.2.1]heptyl; (amino C1-6 Alkylcarbonyl)piperazinyl; (C 1-6 Alkoxypyrrolidinyl)amino; (C 1-6 Alkyl)2AminoC 1-6 Alkoxy; (C 1-6 alkylpyrrolidinylcarbonyl)piperazinyl; (halopyrrolidinyl)amino; 1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl; 3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridinyl; amino(C 1-6 alkyloxy)pyrrolidinyl; aminohalopyrrolidinyl; aminooxopyrrolidinyl or azetidinyl C 1-6 Alkoxy;

[0049] or a pharmaceutically acceptable salt thereof.

[0050] Another embodiment of the present invention is (v), which is a compound of formula (Ib),

[0051]

[0052] in

[0053] R 1 for Where R 4 is cyano, R 5 is H or deuterium;

[0054] R 2 C 1-6 alkyl;

[0055] a) R 3a For (C 1-6 Alkyl)2AminoC 1-6 Alkoxy; (halopyrrolidinyl)amino; (hydroxypyrrolidinyl)C 1-6 Alkylamino; (morpholinyl)C 1-6 Alkylamino or amino-1,4-oxazepanyl;

[0056] R 3b is H; or

[0057] b) R 3a is H;

[0058] R 3b For (amino C 1-6 alkylcarbonyl)-2,5-diazabicyclo[2.2.1]heptyl; (amino C 1-6Alkylcarbonyl)piperazinyl; (C 1-6 Alkoxypyrrolidinyl)amino; (C 1-6 Alkyl)2AminoC 1-6 Alkoxy; (C 1-6 alkylpyrrolidinylcarbonyl)piperazinyl; (halopyrrolidinyl)amino; 1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl; 3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridinyl; amino(C 1-6 alkyloxy)pyrrolidinyl; aminohalopyrrolidinyl; aminooxopyrrolidinyl or azetidinyl C 1-6 Alkoxy;

[0059] or a pharmaceutically acceptable salt thereof.

[0060] A further embodiment of the present invention is (vi), which is a compound of formula (I) or (Ia) or (Ib) according to any one of (i) to (iv), wherein

[0061] R 1 for Where R 4 is cyano, R 5 is H or deuterium;

[0062] R 2 C 1-6 alkyl;

[0063] R 3a is H;

[0064] R 3b For (amino C 1-6 alkylcarbonyl)-2,5-diazabicyclo[2.2.1]heptyl; (amino C 1-6 Alkylcarbonyl)piperazinyl; (C 1-6 Alkoxypyrrolidinyl)amino; (C 1-6 Alkyl)2AminoC 1-6 Alkoxy; (C 1-6alkylpyrrolidinylcarbonyl)piperazinyl; (halopyrrolidinyl)amino; 1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl; 3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridinyl; amino(C 1-6 alkyloxy)pyrrolidinyl; aminohalopyrrolidinyl; aminooxopyrrolidinyl or azetidinyl C 1-6 Alkoxy;

[0065] or a pharmaceutically acceptable salt thereof.

[0066] A further embodiment of the present invention is (vii), which is a compound of formula (I) or (Ia) or (Ib) or a pharmaceutically acceptable salt thereof according to any one of (i) to (vi), wherein R 2 It is methyl.

[0067] A further embodiment of the present invention is (viii), which is a compound of formula (I) or (Ia) or (Ib) or a pharmaceutically acceptable salt thereof according to any one of (i) to (vii), wherein R 3b are (2-amino-2-methyl-propionyl)-2,5-diazabicyclo[2.2.1]heptane-2-yl; (2-amino-2-methyl-propionyl)piperazin-1-yl; (2-methylpyrrolidine-2-carbonyl)piperazin-1-yl; (4-fluoropyrrolidin-3-yl)amino; (4-methoxypyrrolidin-3-yl)amino; (azetidin-2-yl)methoxy; 1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridin-2-yl; 2-(dimethylamino)piperazin-1-yl; )ethoxy; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl; 3-amino-4-fluoro-pyrrolidin-1-yl; 3-amino-4-methoxy-pyrrolidin-1-yl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl; 3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl or 4-amino-2-oxo-pyrrolidin-1-yl.

[0068] A further embodiment of the present invention is (ix), which is a compound of formula (I) or (Ia) or (Ib) or a pharmaceutically acceptable salt thereof according to any one of (i) to (viii), wherein R 3b For (C 1-6alkylpyrrolidinylcarbonyl)piperazinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl or azetidinyl C 1-6 Alkoxy.

[0069] A further embodiment of the present invention is (x), which is a compound of formula (I) or (Ia) or (Ib) according to any one of (i) to (ix), wherein R 3b It is (2-methylpyrrolidine-2-carbonyl)piperazin-1-yl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl or (azetidin-2-yl)methoxy.

[0070] A further embodiment of the present invention is (xi), which is a compound of formula (I) or (Ia) or (Ib) according to any one of (i) to (x), wherein

[0071] R 1 for Where R 4 is cyano, R 5 is H or deuterium;

[0072] R 2 C 1-6 alkyl;

[0073] R 3a is H;

[0074] R 3b For (C 1-6 alkylpyrrolidinylcarbonyl)piperazinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl or azetidinyl C 1-6 Alkoxy;

[0075] or a pharmaceutically acceptable salt thereof.

[0076] Another embodiment of the present invention is (xii) a compound of formula (I) or (Ia) or (Ib) according to any one of (i) to (xi), wherein

[0077] R 1 for Where R 4 is cyano, R 5 is H or deuterium;

[0078] R2 is methyl;

[0079] R 3a is H;

[0080] R 3b is (2-methylpyrrolidine-2-carbonyl)piperazin-1-yl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl or (azetidin-2-yl)methoxy;

[0081] or a pharmaceutically acceptable salt thereof.

[0082] Another embodiment of the present invention is (xiii), which is a compound of formula (I) or (Ia) or (Ib) selected from:

[0083] 5-[(4R,11aS)-8-(6-amino-1,4-oxazepan-4-yl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0084] 5-[(4R,11aS)-8-[2-[(3S)-3-hydroxypyrrolidin-1-yl]ethylamino]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0085] 5-[(4R,11aS)-4-methyl-8-[[(2R)-morpholin-2-yl]methylamino]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0086] 5-[(4R,11aS)-8-[[(3S,4R)-4-fluoropyrrolidin-3-yl]amino]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0087] 5-[(4R,11aS)-8-[2-(dimethylamino)ethoxy]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0088] 5-[(4R,11aS)-4-methyl-9-[[(3R,4S)-4-fluoropyrrolidin-3-yl]amino]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0089] 5-[(4R,11aS)-9-[[(3R,4S)-4-methoxypyrrolidin-3-yl]amino]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0090] 5-[(4R,11aS)-9-[(3S,4R)-3-amino-4-fluoro-pyrrolidin-1-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0091] 5-[(4R,11aS)-9-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0092] 5-[(4R,11aS)-9-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0093] 5-[(4R,11aS)-9-[2-(dimethylamino)ethoxy]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0094] 5-[(4R,11aS)-9-[[(2S)-azetidin-2-yl]methoxy]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0095] 5-[(4R,11aS)-4-methyl-9-[[(3R,4S)-4-fluoropyrrolidin-3-yl]amino]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0096] 5-[(4R,11aS)-4-methyl-9-[4-[(2S)-2-methylpyrrolidine-2-carbonyl]piperazin-1-yl]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0097] 5-[(4R,11aS)-9-[(1S,4S)-5-(2-amino-2-methyl-propionyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0098] 5-[(4R,11aS)-9-(4-amino-2-oxo-pyrrolidin-1-yl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0099] 5-[(4R,11aS)-4-methyl-9-[(8aS)-3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0100] 5-[(4R,11aS)-4-methyl-9-[(8aR)-3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0101] 5-[(4R,11aS)-4-methyl-9-(3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0102] and

[0103] 5-[(4R,11aS)-4-methyl-9-(1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridin-2-yl)-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile;

[0104] or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0105] synthesis

[0106] The compounds of the present invention may be prepared by any conventional method. Suitable methods for synthesizing these compounds and their starting materials are provided in the following schemes and examples. Unless otherwise indicated, all substituents, especially R 1 To R 6As defined above. Furthermore, unless otherwise specifically indicated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to one of ordinary skill in the art of organic chemistry.

[0107] A general synthetic route for preparing compounds of formula (I) is shown in Scheme 1 below.

[0108] Solution 1

[0109]

[0110] Wherein X and Y are halogen or leaving groups, for example, OTf or OMs; R 7 is a protecting group, for example, Boc or benzyl.

[0111] Removal of R from the compound of formula (II) by selective deprotection 7 Afterwards, the resulting compound of formula (III) can be reacted with a compound of formula (IV) in the presence of a base by nucleophilic aromatic substitution to obtain a compound of formula (V), such as DIEPA or Buchwald-Hartwig amination conditions (e.g., heating with a halide (IV)) in the presence of a catalyst (e.g., RuphosPd-G2) and a base (e.g., Cs2CO3). A compound of formula (I) or (Ia) or (Ib) can be reacted with a compound of formula (V) by metal-catalyzed coupling conditions. 3 -H(R 3 -H can be an amine or an alcohol) reaction: Buchwald-Hartwig amination in the presence of a catalyst (such as Ruphos Pd-G2) and a base (such as Cs2CO3); in the presence of a palladium catalyst (such as tetrakis(triphenylphosphine)palladium(0) or [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)), complexed with dichloromethane and a base (such as potassium carbonate) in a solvent, and with R 3 Boric acid, R 3 Suzuki coupling with boronate; Stille coupling with organotin reagent in the presence of palladium(0) catalyst (e.g., tetrakis(triphenylphosphine)palladium(0)); or Negishi coupling with organozinc reagent in the presence of palladium(0) catalyst (e.g., tetrakis(triphenylphosphine)palladium(0) or [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)). In some embodiments, the protecting group (e.g., Boc) will be removed and can be further modified by amide formation reaction before obtaining the final compound of formula (I) or (Ia) or (Ib).

[0112] The compounds of the present invention can be obtained as diastereomers or mixtures of enantiomers, which can be separated by methods well known in the art, for example, (chiral) HPLC or SFC. In another embodiment, compounds of formula (Ia) or (Ib) can be obtained according to the above scheme by using the corresponding chiral starting materials.

[0113] The compounds of the invention may be obtained in the form of diastereomers or mixtures of enantiomers which may be separated by methods well known in the art, for example, (chiral) HPLC or SFC.

[0114] The present invention also relates to a method for preparing a compound of formula (I) or (Ia), the method comprising the following steps:

[0115] a) a compound of formula (V),

[0116]

[0117] and R 3 -H by Buchwald-Hartwig amination or Suzuki coupling or Stille coupling or Negishi coupling; wherein R 3 -H is an amine or an alcohol;

[0118] The preparation of compounds of formula (I) or (Ia) or (Ib) according to the above-mentioned process using achiral or chiral starting materials is also an object of the present invention.

[0119] Indications and treatments

[0120] The present invention provides compounds that can be used as TLR7 and / or TLR8 and / or TLR9 antagonists, which inhibit activation of TLR7 and / or TLR8 and / or TLR9 pathways and corresponding downstream biological events, including but not limited to innate and adaptive immune responses mediated by the production of all types of cytokines and various forms of autoantibodies. Therefore, the compounds of the present invention can be used to block TLR7 and / or TLR8 and / or TLR9 in all types of cells expressing such receptors, including but not limited to plasmacytoid dendritic cells, B cells, T cells, macrophages, monocytes, neutrophils, keratinocytes, epithelial cells. In this way, the compound can be used as a therapeutic agent or preventive for systemic lupus erythematosus and lupus nephritis.

[0121] The present invention provides methods for treating or preventing systemic lupus erythematosus and lupus nephritis in a patient in need thereof.

[0122] Another embodiment includes a method of treating or preventing systemic lupus erythematosus and lupus nephritis in a mammal in need of such treatment, wherein the method comprises administering to the mammal a therapeutically effective amount of a compound of formula (I), a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof.

[0123] Examples

[0124] The present invention will be more fully understood by referring to the following examples. However, they should not be construed as limiting the scope of the present invention.

[0125] abbreviation

[0126] The present invention will be more fully understood by referring to the following examples. However, they should not be construed as limiting the scope of the present invention.

[0127] The abbreviations used in this article are as follows:

[0128] ACN: Acetonitrile

[0129] DCM: Dichloromethane

[0130] EA or EtOAc: Ethyl acetate

[0131] FA: Formic acid

[0132] HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate

[0133] hr hours

[0134] hrs hours

[0135] IC 50 : Half inhibitory concentration

[0136] LCMS Liquid chromatography-mass spectrometry

[0137] MS: mass spectrometry

[0138] PE: Petroleum ether

[0139] prep-HPLC: Preparative High Performance Liquid Chromatography

[0140] rt: rt

[0141] RuPhos Pd G2: Chloro(2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) second generation

[0142] SFC: Supercritical Fluid Chromatography

[0143] TFA: trifluoroacetic acid

[0144] v / v volume ratio

[0145] General experimental conditions

[0146] Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SP1 system and Quad 12 / 25 Cartridge module. ii) ISCO combi-flash chromatograph. Silica gel brand and pore size: i) KP-SIL Particle size: 40-60 μm; ii) CAS registration number: silica gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Ocean Chemical Co., Ltd., pore size: 200-300 or 300-400.

[0147] Intermediates and final compounds were purified by preparative HPLC on a reverse phase column using XBridge TM Prep-C18 (5μm, OBDTM 30×100mm) column, SunFire TM Prep-C18(5μm,OBD TM 30×100mm) chromatographic column, Phenomenex Synergi-C18 (10μm, 25×150mm) or Phenomenex Gemini-C18 (10μm, 25×150mm). Waters AutoP purification system (sample manager 2767, pump 2525, detector: Micromass ZQ and UV 2487, solvent system: acetonitrile and 0.1% ammonium hydroxide in water; acetonitrile and 0.1% FA in water, or acetonitrile and 0.1% TFA in water). Or Gilson-281 purification system (pump 322, detector: UV 156, solvent system: acetonitrile and 0.05% ammonium hydroxide in water; acetonitrile and 0.225% FA in water; acetonitrile and 0.05% HCl in water; acetonitrile and 0.075% TFA in water; or acetonitrile and water).

[0148] For SFC chiral separation, the intermediates were separated by chiral columns (Daicel chiralpak IC, 5 μm, 30×250 mm), AS (10 μm, 30×250 mm) or AD (10 μm, 30×250 mm), using Mettler Toledo Multigram III system SFC, Waters 80Q preparative SFC or Thar 80 preparative SFC, solvent system: CO2 and IPA (0.5% TEA in IPA solution) or CO2 and MeOH (0.1% NH3·H2O in MeOH solution), back pressure 100 bar, UV detection at 254 or 220 nm.

[0149] Using LC / MS (Waters TM The LC / MS spectra of the compounds were obtained using an Agilent Alliance 2795-Micromass ZQ, Shimadzu Alliance 2020-Micromass ZQ, or Agilent Alliance 6110-Micromass ZQ. The LC / MS conditions were as follows (run time 3 or 1.5 min):

[0150] Acidic conditions I: A: 0.1% TFA solution in H2O; B: 0.1% TFA solution in acetonitrile;

[0151] Acidic conditions II: A: 0.0375% TFA solution in H2O; B: 0.01875% TFA solution in acetonitrile;

[0152] Basic conditions I: A: 0.1% NH3·H2O solution in H2O; B: acetonitrile;

[0153] Basic conditions II: A: 0.025% NH3·H2O solution in H2O; B: acetonitrile;

[0154] Neutral conditions: A: H2O; B: acetonitrile.

[0155] Mass spectra (MS): Usually only ions representing the parent mass are reported, and unless otherwise stated, the mass ion quoted is the positive mass ion (MH) + .

[0156] NMR spectra were obtained using a Bruker Avance 400 MHz.

[0157] Microwave-assisted reactions were performed in a Biotage Initiator Sixty microwave synthesizer. All reactions involving air-sensitive reagents were performed under argon or nitrogen atmosphere. Unless otherwise stated, reagents were used as received from commercial suppliers without further purification.

[0158] Preparation Example

[0159] The following examples are intended to illustrate the meaning of the present invention, but are by no means intended to limit the meaning of the present invention:

[0160] Intermediate A

[0161] 5-Fluoroquinoline-8-carbonitrile

[0162]

[0163] The title compound was synthesized according to the following scheme:

[0164]

[0165] Step (a): Preparation of 8-bromo-5-fluoro-quinoline (Compound A2)

[0166] In a 100 mL pear-shaped flask, 2-bromo-5-fluoroaniline (Compound A1, 2.0 g, 10.5 mmol), propane-1,2,3-triol (969 mg, 10.5 mmol) and sodium 3-nitrobenzenesulfonate (2.4 g, 10.5 mmol) were combined with 70% H2SO4 (20 mL) to give a dark brown solution, which was heated to 150°C and stirred for 3 hours. After cooling to room temperature, the reaction mixture was poured into ice water and neutralized with sodium hydroxide solution. The resulting mixture was filtered. The filter cake was dissolved in EtOAc and filtered. The resulting filtrate was concentrated in vacuo. The crude material was purified by flash chromatography (silica gel, 40 g, 0% to 30% EtOAc in PE) to give Compound A2 (2.0 g, 84% yield). MS: calc'd 226 and 228 [(M+H) + ], measured values ​​are 226 and 228 [(M+H) + ].

[0167] Step (b): Preparation of 5-fluoroquinoline-8-carbonitrile (Intermediate A)

[0168] To a solution of 8-bromo-5-fluoroquinoline (Compound A2, 4.9 g, 21.7 mmol) in DMF (30 mL) was added dicyanozinc (5.0 g, 43.4 mmol) and RuPhos Pd G2 (CAS: 1375325-68-0, Sigma-Aldrich, Catalog: 753246, 842 mg, 1.1 mmol). The reaction mixture was stirred at 100 °C for 3 hours and then cooled to room temperature. The reaction mixture was filtered and the filtrate was diluted with water (50 ml) and then extracted three times with EA (80 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 40 g, 0% to 70% EtOAc in PE) to give Intermediate A1 (3.0 g, 80% yield). MS: calc'd 173 [(M+H) + ], the measured value is 173[(M+H) + ]. 1 HNMR(400MHz,METHANOL-d4)δppm 9.11(dd,J=4.28,1.71Hz,1H),8.64(dd,J=8.56,1.71Hz,1H),8.29(dd,J=8.1 9,5.62Hz,1H),7.76(dd,J=8.56,4.28Hz,1H),7.49(dd,J=9.35,8.25Hz,1H).

[0169] Intermediate B

[0170] 5-[(4R,11aS)-8-Bromo-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0171]

[0172] The title compound was synthesized according to the following scheme:

[0173]

[0174] Step (a): Preparation of methyl (2S)-3-(4-bromophenyl)-2-(methoxycarbonylamino)propanoate (Compound B2)

[0175] To a solution of (S)-2-amino-3-(4-bromophenyl)propionic acid methyl ester hydrochloride (CAS: 880347-43-3, Bepharm, catalog number: BD00815750) (Compound B1, 9 g, 30.6 mmol) in DCM (100 mL) was added pyridine (6.0 g, 6.2 mL, 76.4 mmol) and methyl chloroformate (5.8 g, 61.1 mmol). The reaction mixture was stirred at room temperature overnight, and then the mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc and washed with aqueous NaHCO3 solution, 1N HCl aqueous solution, and brine, respectively. The organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with 25% ethyl acetate in hexane to give Compound B2 (8.5 g, 88% yield). MS: calc'd 316 [(M+H) + ], the measured value is 316[(M+H) + ].

[0176] Step (b): Preparation of dimethyl (3S)-7-bromo-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylate (Compound B3)

[0177] To a mixture of (S)-3-(4-bromophenyl)-2-((methoxycarbonyl)amino)propanoic acid methyl ester (Compound B2, 8.5 g, 26.9 mmol) and paraformaldehyde (1.61 g, 53.8 mmol) was added a mixture of concentrated sulfuric acid (20 mL) and acetic acid (30 mL). The resulting mixture was stirred at room temperature for 20 hours. The reaction mixture was poured into ice water and extracted with DCM. The organic layer was washed with water, saturated NaHCO3 aqueous solution and brine, respectively, and dried over MgSO4. After filtration, the filtrate was concentrated and the residue was purified by flash chromatography (silica gel, 120 g, 0% to 70% EtOAc in hexane) to give Compound B3 (5.9 g, 66.9% yield). MS: calculated value is 328 [(M+H) + ], the measured value is 328[(M+H) + ].

[0178] Step (c): Preparation of (3S)-7-bromo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester (Compound B4)

[0179] To a solution of (S)-7-bromo-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylic acid dimethyl ester (Compound B3, 5.9 g, 18.0 mmol) in DCM (40 mL) was added iodotrimethylsilane (14.4 g, 71.9 mmol). The resulting mixture was stirred at 50 °C for 2 hours. After cooling to room temperature, methanol (40 mL) was added, and the reaction mixture was stirred for 30 minutes. The reaction mixture was concentrated in vacuo, and the residue was diluted with diethyl ether and filtered. The collected solid was washed with ether and dried in vacuo to give Compound B4 (4.6 g, 94.7% yield), which was used directly in the next step without further purification. MS: calc'd 270 [(M+H) + ], the measured value is 270[(M+H) + ].

[0180] Step (d): Preparation of (3S)-7-bromo-2-[2-(tert-butoxycarbonylamino)-1-methyl-ethyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid methyl ester (Compound B5)

[0181] To a methanol solution (40 mL) of (S)-7-bromo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester (Compound B4, 4.6 g, 17 mmol) and tert-butyl (2-oxopropyl)carbamate (4.42 g, 25.5 mmol) was added 0.5 mL of HOAc. After the mixture was stirred and refluxed for 2 hours, NaBH3CN (2.1 g, 34.1 mmol) was added. Then, the reaction mixture was stirred and refluxed overnight. After the mixture was cooled to room temperature, it was diluted with water (100 mL) and extracted three times with EA (100 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated. The residue was purified by flash chromatography (silica gel, 80 g, 0% to 70% EtOAc in PE) to give Compound B5 (3.28 g, 45.1% yield). MS: Calculated value is 427 [(M+H) + ], the measured value is 427[(M+H) + ].

[0182] Step (e): Preparation of (11aS)-8-bromo-4-methyl-2,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-1-one (Compound B6)

[0183] A mixture of (3S)-7-bromo-2-[2-(tert-butoxycarbonylamino)-1-methyl-ethyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid methyl ester (Compound B5, 2.2 g, 5.2 mmol) and HCl / MeOH (10% W / W; 50 mL) was stirred at 60°C overnight. After cooling to room temperature, the reaction mixture was basified with saturated K2CO3(aq) to pH ca. 8 and extracted three times with EA (80 mL). The combined organic layers were washed with brine (50 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 40 g, 0% to 20% MeOH in DCM) to give Compound B6 (780 mg, 51.3% yield). MS: calc'd 295[(M+H) + ], the measured value is 295[(M+H) + ].

[0184] Step (f): Preparation of (11aS)-8-bromo-4-methyl-2,3,4,6,11,11a-hexahydro-1H-pyrazino[1,2-b]isoquinoline (Compound B7)

[0185] A mixture of (11aS)-8-bromo-4-methyl-2,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-1-one (Compound B6, 760 mg, 2.57 mmol) and BH3 solution (1 M in THF, 30 mL, 30 mmol) was heated at 80°C and stirred for 5 hours. HCl solution (6N, 5 mL) was slowly added to the reaction mixture at 0°C. After stirring at 80°C for 2 hours, the mixture was cooled to room temperature, basified with 2N NaOH solution (aq) to pH 10, and extracted twice with EtOAc. The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo to give Compound B7 (710 mg, 98.1% yield). MS: calc'd 281 [(M+H) + ], the measured value is 281[(M+H) + ].

[0186] Step (g): Preparation of 5-[(4R,11aS)-8-bromo-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile (Intermediate B)

[0187] To a solution of (11aS)-8-bromo-4-methyl-2,3,4,6,11,11a-hexahydro-1H-pyrazino[1,2-b]isoquinoline (Compound B7, 710 mg, 2.5 mmol) in DMSO (10 mL) was added 5-fluoroquinoline-8-carbonitrile (Intermediate A, 435 mg, 2.5 mmol) and DIEA (1.63 g, 2.2 mL, 12.6 mmol). The resulting mixture was stirred at 120 °C for 20 hours. After cooling to room temperature, the reaction (mixture) was diluted with water (50 mL) and extracted twice with EA (80 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 40 g, 0% to 100% EtOAc in PE) to afford Intermediate B (510 mg, 46.6% yield) and compound B8 (230 mg, 21% yield). The stereochemistry was confirmed by NOESY.

[0188] Intermediate B MS: calculated value: 433 [(M+H) + ], the measured value is 433[(M+H) + ]. 1 H NMR (400MHz, methanol-d4) δppm 9.00(dd,J=4.22,1.65Hz,1H),8.64(dd,J=8.56,1.59Hz,1H),8.15(d,J=8.07Hz,1H),7.65(dd,J=8.56,4.28Hz,1H),7.35(s,1H),7.31(d d,J=8.13,1.90Hz,1H),7.25(d,J=7.95Hz,1H),7.05(d,J=8.19Hz,1H),4.37(d,J=15.65Hz,1H),3.60(dt,J=11.83,2.83Hz,1H),3.46(br d,J=2.57Hz,1H),3.45-3.37(m,1H),3.02-2.94(m,1H),2.91-2.83(m,1H), 2.88-2.82(m,1H),2.87-2.80(m,1H),2.74-2.63(m,1H),1.37-1.29(m,3H).

[0189] Compound B8 MS: calculated value: 433 [(M+H) + ], the measured value is 433[(M+H) + ]. 1H NMR (400MHz, methanol-d4) δppm 8.99(dd,J=4.22,1.65Hz,1H),8.69(dd,J=8.56,1.59Hz,1H),8.17(d,J=8.07Hz,1H),7.6 6(dd,J=8.56,4.28Hz,1H),7.39-7.22(m,3H),7.10(d,J=8.19Hz,1H),4.08-3.98(m,2H), 3.62-3.47(m,2H),3.39(dd,J=11.80,2.02Hz,1H),3.36-3.43(m,1H),3.28-3.17(m,1H), 3.16-3.09(m,1H),3.08-2.97(m,1H),2.82(dd,J=17.06,4.95Hz,1H),1.34-1.28(m,3H).

[0190] Intermediate C

[0191] 5-[(4R,11aS)-9-Bromo-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0192]

[0193] The title compound was prepared similarly to the preparation of intermediate B by using (S)-2-amino-3-(3-bromophenyl)propionic acid methyl ester hydrochloride (CAS: 875782-96-0, Bepharm, catalog number: BD00869561) instead of (S)-2-amino-3-(4-bromophenyl)propionic acid methyl ester hydrochloride in step (a). Intermediate C was obtained. MS: calc'd 433 [(M+H) + ], the measured value is 433[(M+H) + ]. 1 H NMR (chloroform-d, 400 MHz) δ 9.08 (dd, 1H, J = 1.6, 4.2 Hz), 8.49 (dd, 1H, J = 1.7, 8.6 Hz), 8.05 (d, 1H, J = 7.9 Hz), 7.52 (dd, 1H, J = 4.2, 8.6 Hz), 7.29 (d, 1H, J = 8.2 Hz), 7.26 (br s, 1H), 7.11 (d, 1H, J = 8.1 Hz), 6.98 (d, 1H, J = 8.2 Hz), 4.30 (d, 1H, J = 15.2 Hz), 3.5-3.6 (m, 1H), 3.3-3.4 (m, 2H), 2.7-3.0 (m, 5H), 1.29 (d, 3H, J = 6.1 Hz). The stereochemistry was confirmed by NOESY.

[0194] Example 1

[0195] 5-[(4R,11aS)-8-(6-amino-1,4-oxazepan-4-yl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0196]

[0197] The title compound was synthesized according to the following scheme:

[0198]

[0199] Step (a): Preparation of tert-butyl N-[4-[(4R,11aS)-2-(8-cyano-5-quinolyl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-8-yl]-1,4-oxazepan-6-yl]carboxylate (Compound 1.1)

[0200] To a solution of tert-butyl N-(1,4-oxazepan-6-yl)carbamate (CAS: 1782916-90-8, PharmaBlock, catalog: PB95734, 60 mg, 277 μmol) in dioxane (5 mL) was added 5-((4R, 11aS)-8-bromo-4-methyl-1,3,4,6,11,11a-hexahydro-2H-pyrazino[1,2-b]isoquinolin-2-yl)quinoline-8-carbonitrile (Intermediate B1, 120 mg, 277 μmol), tBuONa (53.3 mg, 555 μmol) and tBuXPhos Pd G3 (CAS: 1447963-75-8, Sigma-Aldrich, catalog: 762229, 22 mg, 27.7 μmol). The resulting mixture was stirred at 90° C. overnight. After the mixture was cooled to room temperature, it was diluted with water (20 mL) and extracted three times with EA (20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 24 g, 0% to 100% EtOAc in PE) to give compound 1.1 (33 mg, 20.9% yield). MS: calc'd 569 [(M+H) + ], the measured value is 569[(M+H) + ].

[0201] Step (b): Preparation of 5-[(4R,11aS)-8-(6-amino-1,4-oxazepan-4-yl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile (Example 1)

[0202] To a solution of tert-butyl N-[4-[(4R,11aS)-2-(8-cyano-5-quinolyl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-8-yl]-1,4-oxazepan-6-yl]carboxylate (compound 1.1, 21 mg, 38 μmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 30 minutes and then concentrated to give the crude product, which was purified by preparative HPLC to give Example 1 (9 mg, 50.6% yield). MS: calc'd 469 [(M+H) + ], the measured value is 469[(M+H) + ]. 1 H NMR (400MHz, methanol-d4) δppm 9.09-8.96(m,1H),8.76-8.60(m,1H),8.20(d,J=7.9Hz,1H),7.74-7.64(m,1H),7.35(d,J=7.9Hz,1H),7.10(d,J=8.6Hz,1H),6.88-6 .80(m,1H),6.74(s,1H),4.67(d,J=15.3Hz,1H),4.18-4.10(m,1H),4.07-3.75(m,7H),3.69-3.43(m,6H),3.12-2.97(m,3H),2.87(br d,J=11.9Hz,1H), 1.49 (d,J=6.2Hz,3H).

[0203] Example 2

[0204] 5-[(4R,11aS)-8-[2-[(3S)-3-hydroxypyrrolidin-1-yl]ethylamino]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0205]

[0206] The title compound was prepared similarly to the preparation of Example 1 by using (3S)-1-(2-aminoethyl)pyrrolidin-3-ol (CAS: 540787-75-5, Bide Pharmatech, catalog: BD45313) instead of tert-butyl N-(1,4-oxazepan-6-yl)carboxylate in step (a). Example 2 was obtained. MS: calc'd 483 [(M+H) + ], the measured value is 483[(M+H) + ]. 1 H NMR (400MHz, methanol-d4) δppm 9.05-8.98(m,1H),8.73-8.64(m,1H),8.20(d,J=7.9Hz,1H),7.72-7.63(m,1H),7.35(d,J=8.1Hz,1 H),7.03(d,J=8.3Hz,1H),6.83-6.63(m,1H),6.58(d,J=2.2Hz,1H),4.67(d,J=15.4Hz,1H),4.63-4 .56(m,1H),4.00(d,J=15.2Hz,1H),3.83-3.74(m,1H),3.72-3.60(m,3H),3.59-3.40(m,8H),3.14- 2.94(m,3H),2.88(brd,J=11.5Hz,1H),2.35-2.19(m,1H),2.15-2.02(m,1H),1.50(d,J=6.4Hz,3H).

[0207] Example 3

[0208] 5-[(4R,11aS)-4-methyl-8-[[(2S)-morpholin-2-yl]methylamino]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0209]

[0210] The title compound was prepared similarly to the preparation of Example 1 by using (2S)-2-(aminomethyl)morpholine-4-carboxylic acid tert-butyl ester (CAS: 879403-42-6, PharmaBlock, catalog: PBN20121306) instead of N-(1,4-oxazepan-6-yl)carboxylic acid tert-butyl ester in step (a). Example 3 was obtained. MS: calc'd 469 [(M+H) + ], the measured value is 469[(M+H) + ]. 1H NMR (400MHz, methanol-d4) δppm 9.09-8.97(m,1H),8.77-8.64(m,1H),8.21(d,J=7.9Hz,1H),7.79-7.58(m,1H),7.39(d ,J=8.1Hz,1H),7.03(d,J=8.4Hz,1H),6.75-6.64(m,1H),6.57(d,J=2.2Hz,1H),4.87(br d,J=15.5Hz,1H),4.36(d,J=15.4Hz,1H),4.18-4.05(m,2H),4.02-3.70(m,5H),3.43(br d,J=12.5Hz,1H),3.32-2.90(m,9H),1.62(d,J=6.5Hz,3H).

[0211] Example 4

[0212] 5-[(4R,11aS)-8-[[(3S,4R)-4-fluoropyrrolidin-3-yl]amino]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0213]

[0214] The title compound was prepared similarly to the preparation of Example 1 by using (3S,4R)-3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester (CAS: 1174020-30-4, PharmaBlock, catalog: PB07374) instead of N-(1,4-oxazepan-6-yl)carboxylic acid tert-butyl ester in step (a). Example 4 was obtained. MS: calc'd 457 [(M+H) + ], the measured value is 457[(M+H) + ]. 1H NMR (400MHz, methanol-d4) δppm 9.09-8.98(m,1H),8.74-8.65(m,1H),8.19(d,J=7.9Hz,1H),7.72-7.65(m,1H),7.34(d,J=8.1Hz,1H),7.03(d,J=8.4H z,1H),6.79-6.71(m,1H),6.65(d,J=2.0Hz,1H),5.44-5.22(m,1H),4.61(d,J=15.2Hz,1H),4.52-4.38(m,1H),3.92(br d,J=15.2Hz,1H),3.84-3.37(m,7H),3.24(t,J=11.2Hz,1H),3.12-2.94(m,3H),2.86(br d,J=11.7Hz,1H),1.47(d,J=6.2Hz,3H).

[0215] Example 5

[0216] 5-[(4R,11aS)-8-[2-(dimethylamino)ethoxy]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0217]

[0218] The title compound was prepared similarly to the preparation of Example 1 by using 2-(dimethylamino)ethanol (CAS: 108-01-0, Sigma-Aldrich, catalog: 38990) instead of tert-butyl N-(1,4-oxazepan-6-yl)carbamate in step (a). Example 5 was obtained. MS: calc'd 442 [(M+H) + ], the measured value is 442[(M+H) + ]. 1 H NMR (400 MHz, methanol-d4) δppm8.89-8.81 (m, 1H), 8.60-8.45 (m, 1H), 8.04 (d, J = 7.9 Hz, 1H), 7.60-7.47 (m, 1H), 7.17 (d, J = 8.1 Hz, 1H), 7.00 (d, J = 8.6 Hz, 1H), 6.81-6.71 (m, 2H), 4. 42(d,J=15.5Hz,1H),4.24-4.15(m,2H),3.68-3.53(m,2H),3.50-3.38(m,3H),3.12-3 .02(m,1H),2.90-2.76(m,4H),2.86(s,6H),2.72-2.61(m,1H),1.27(d,J=6.4Hz,3H).

[0219] Example 6

[0220] 5-[(4R,11aS)-4-methyl-9-[[(3R,4S)-4-fluoropyrrolidin-3-yl]amino]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0221]

[0222] The reaction mixture was prepared similarly to Example 1 by using (3R,4S)-3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester (CAS: 1009075-48-2, PharmaBlock, catalog: PB07375) instead of N-(1,4-oxazepan-6-yl)carbamic acid tert-butyl ester and 5-[(4R,11aS)-9-bromo-1,1,1,1,1,4 -Hexamethyl-4,6,11,11a-tetrahydro-3H-pyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile (Intermediate C) was used to replace 5-[(4R,11aS)-8-bromo-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile (Intermediate B) in step (a) to prepare the title compound. Example 6 was obtained. MS: calc'd 457 [(M+H) + ], the measured value is 457[(M+H) + ]. 1 H NMR (methanol-d4, 400MHz) δ8.92 (dd, 1H, J = 1.5, 4.3Hz), 8.60 (dd, 1H, J = 1.5, 8.6Hz), 8.10 (d, 1H, J = 7.9Hz), 7.59 (dd, 1H, J = 4.3, 8.6 Hz),7.29(d,1H,J=7.9Hz),7.02(d,1H,J=8.6Hz),6.66(dd,1H,J=2.1,8.4Hz),6.54(d,1H,J=1.8Hz),5.1-5.4(m,1H),4.80(br d,1H,J=15.0Hz),4.3-4.4(m,1H),4.22(br d,1H,J=15.0Hz),4.04(br t,1H,J=10.9Hz),3.8-3.9(m,2H),3.4-3.8(m,4H),3.0-3.2(m,4H),2.8-3.0(m,1H),1.50(d,3H,J=6.5Hz).

[0223] Example 7

[0224] 5-[(4R,11aS)-9-[[(3R,4S)-4-methoxypyrrolidin-3-yl]amino]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0225]

[0226] The title compound was prepared similarly to the preparation of Example 6 by using ((3R,4S)-3-amino-4-methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester (CAS: 148260-94-0, BePharm, catalog: BD285562) instead of (3R,4S)-3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester in step (a). Example 7 was obtained. MS: calc'd 469 [(M+H + ], the measured value is 469[(M+H) + ]. 1 H NMR (methanol-d4, 400MHz) δ9.06 (dd, 1H, J = 1.6, 4.3Hz), 8.73 (dd, 1H, J = 1.6, 8.6Hz), 8.25 (d, 1H, J = 7.9Hz), 7.72 (dd, 1H, J = 4.3, 8.6Hz), 7.42 (d, 1H, J = 7.9Hz), 7.14 (d, 1H, J = 8.4Hz), 6.77 (dd, 1H, J = 2.3, 8.4Hz), 6.64 (d, 1H, J = 2.0Hz), 4.93 (br d,1H,J=14.1Hz),4.3-4.4(m,2H),4.1-4.2(m,2H),4.0-4.0(m,1H),3.9-4.0(m,1H),3.8-3.9 (m,1H),3.6-3.7(m,2H),3.42(s,3H),3.1-3.3(m,5H),3.0-3.1(m,1H),1.62(d,3H,J=6.5Hz).

[0227] Example 8

[0228] 5-[(4R,11aS)-9-[(3S,4R)-3-amino-4-fluoro-pyrrolidin-1-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0229]

[0230] The title compound was prepared similarly to the preparation of Example 6 by using N-[(3S,4R)-4-fluoropyrrolidin-3-yl]carbamic acid tert-butyl ester (CAS: 1033718-89-6, PharmaBlock, catalog: PB09206) instead of (3R,4S)-3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester in step (a). Example 8 was obtained. MS: calc'd 457 [(M+H) + ], the measured value is 457[(M+H) + ]. 1 H NMR (methanol-d4, 400 MHz) δ ppm 9.06(dd,1H,J=1.6,4.3Hz),8.73(dd,1H,J=1.7,8.6Hz),8.24(d,1H,J=7.9Hz ),7.72(dd,1H,J=4.2,8.5Hz),7.41(d,1H,J=8.1Hz),7.21(d,1H,J=8.7Hz),6. 66(dd,1H,J=2.3,8.3Hz),6.51(d,1H,J=1.7Hz),5.3-5.6(m,1H),4.0-4.4(m,3 H),3.7-4.0(m,6H),3.4-3.5(m,3H),3.1-3.3(m,2H),3.0-3.1(m,1H),1.59(br d, 3H, J = 6.5 Hz).

[0231] Example 9

[0232] 5-[(4R,11aS)-9-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0233]

[0234] The title compound was prepared similarly to the preparation of Example 6 by using N-[(3R,4S)-4-methoxypyrrolidin-3-yl]carbamic acid tert-butyl ester (CAS: 1932508-77-4, PharmaBlock, catalog: PBZ4729) instead of (3R,4S)-3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester in step (a). Example 9 was obtained. MS: calc'd 469 [(M+H) + ], the measured value is 469[(M+H) + ]. 1H NMR (methanol-d4, 400MHz) δ9.06 (dd, 1H, J = 1.6, 4.3Hz), 8.73 (dd, 1H, J = 1.6, 8.6Hz), 8.24 (d, 1H, J = 7.9Hz), 7.72 (dd, 1H, J = 4.3, 8.6Hz),7.41(d,1H,J=7.9Hz),7.19(d,1H,J=8.4Hz),6.64(dd,1H,J=1.8,8.8Hz),6.49(d,1H,J=1.6Hz),4.7-4.8(m,1H), 4.2-4.3(m,1H),4.1-4.2(m,1H),4.0-4.1(m,1H),3.9-4.0(m,1H),3.8-3.9(m,1H),3.8-3.8(m,1H),3.6-3.7(m,1H),3.5- 3.6(m,1H),3.4-3.5(m,2H),3.4-3.4(m,3H),3.32(dd,1H,J=6.7,9.8Hz),3.0-3.2(m,3H),2.9-3.0(m,1H),1.4-1.6(m,3H)

[0235] Example 10

[0236] 5-[(4R,11aS)-9-[(4aR,7aR)-3,4,4a,5,7,7a-Hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0237]

[0238] The title compound was prepared similarly to the preparation of Example 6 by using (4aR,7aR)-3,4a,5,6,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazine-4-carboxylic acid tert-butyl ester (CAS: 1932337-68-2, PharmaBlock, catalog: PBXA8123) instead of (3R,4S)-3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester in step (a). Example 10 was obtained. MS: calc'd 481 [(M+H) + ], the measured value is 481[(M+H) + ]. 1H NMR (methanol-d4, 400MHz) δ9.06 (dd, 1H, J = 1.5, 4.2Hz), 8.73 (dd, 1H, J = 1.7, 8.6Hz), 8.25 (d, 1H, J = 7.9Hz), 7.72 (dd, 1H, J = 4.3,8.7Hz),7.42(d,1H,J=7.9Hz),7.20(d,1H,J=8.6Hz),6.64(dd,1H,J=2.2,8.8Hz),6.48(d,1H,J=2.4Hz),4.90(br d,1H,J=15.0Hz),4.36(br d,1H,J=15.0Hz),4.28(dd,1H,J=3.9,13.4Hz),3.9-4.2(m,5H),3.7-3.9(m,3H),3.4-3.7(m,4H),3.0-3.3(m,5H),1.62(d,3H,J=6.5Hz).

[0239] Example 11

[0240] 5-[(4R,11aS)-9-[2-(dimethylamino)ethoxy]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0241]

[0242] The title compound was prepared similarly to the preparation of Example 6 by using 2-(dimethylamino)ethanol instead of (3R,4S)-3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester in step (a). Example 11 was obtained. MS: calc'd 442 [(M+H) + ], the measured value is 442[(M+H) + ]. 1H NMR (methanol-d4, 400MHz) δ9.03 (dd, 1H, J = 1.5, 4.3Hz), 8.72 (dd, 1H, J = 1.5, 8.7Hz), 8.22 (d, 1H, J = 7.9Hz), 7.71 (dd, 1H, J = 4.2,8.6Hz),7.41(d,1H,J=7.9Hz),7.31(d,1H,J=8.7Hz),7.04(dd,1H,J=2.4,8.6Hz),6.96(d,1H,J=2.2Hz),5.00(br d,1H,J=15.3Hz),4.3-4.5(m,3H),4.19(br t,1H,J=10.3Hz),3.9-4.1(m,2H),3.80(br d,1H,J=13.3Hz),3.5-3.7(m,2H),3.2-3.3(m,3H),3.13(br dd,1H,J=11.9,17.7Hz),3.01(s,6H),1.64(d,3H,J=6.5Hz).

[0243] Example 12

[0244] 5-[(4R,11aS)-9-[[(2S)-azetidin-2-yl]methoxy]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0245]

[0246] The title compound was prepared similarly to the preparation of Example 6 by using (2S)-2-(hydroxymethyl)azetidine-1-carboxylic acid tert-butyl ester (CAS: 161511-85-9, PharmaBlock, catalog: PB03034) instead of (3R, 4S)-3-amino-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester in step (a). Example 12 was obtained. MS: calc'd 440 [(M+H) + ], the measured value is 440[(M+H) + ]. 1H NMR (methanol-d4, 400MHz) δ9.06 (dd, 1H, J = 1.7, 4.2Hz), 8.73 (dd, 1H, J = 1.6, 8.6Hz), 8.25 (d, 1H, J = 7.9Hz), 7.73 (dd, 1H, J = 4.3,8.6Hz),7.43(d,1H,J=8.1Hz),7.33(d,1H,J=8.7Hz),7.07(dd,1H,J=2.4,8.5Hz),6.98(d,1H,J=2.3Hz),5.01(br d,1H,J=15.0Hz),4.41(br d,1H,J=15.0Hz),4.35(d,2H,J=4.6Hz),3.9-4.3(m,6H),3.8-3.9(m,1H),3.1-3.3(m,4H),2.6-2.8(m,2H),1.63(d,3H,J=6.5Hz).

[0247] Example 13

[0248] 5-[(4R,11aS)-4-methyl-9-[[(3R,4S)-4-fluoropyrrolidin-3-yl]amino]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0249]

[0250] The title compound was synthesized according to the following scheme:

[0251]

[0252] Step (a): Preparation of tert-butyl 4-[(4R,11aS)-2-(8-cyano-5-quinolyl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-9-yl]piperazine-1-carboxylate (Compound 13.1)

[0253] To a solution of tert-butyl piperazine-1-carboxylate (60 mg, 322 μmol) in dioxane (5 mL) was added 5-((4R, 11aS)-9-bromo-4-methyl-1,3,4,6,11,11a-hexahydro-2H-pyrazino[1,2-b]isoquinolin-2-yl)quinoline-8-carbonitrile (Intermediate C, 139.4 mg, 277 μmol), tBuONa (61.9 mg, 644 μmol) and tBuXPhos Pd G3 (CAS: 1447963-75-8, Sigma-Aldrich, Catalog: 762229, 25.6 mg, 32.2 μmol). The resulting mixture was stirred at 90° C. overnight. After cooling to room temperature, the mixture was diluted with water (20 mL) and extracted three times with EA (20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 24 g, 0% to 100% EtOAc in PE) to give compound 13.1 (26.1 mg, 35% yield). MS: calc'd 539 [(M+H) + ], the measured value is 539[(M+H) + ].

[0254] Step (b): Preparation of 5-[(4R,11aS)-4-methyl-9-piperazin-1-yl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile (Compound 13.2)

[0255] To a solution of tert-butyl 4-[(4R,11aS)-2-(8-cyano-5-quinolyl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-9-yl]piperazine-1-carboxylate (compound 13.1, 26.1 mg, 48.5 μmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, quenched with saturated aq. NaHCO3, washed with brine and dried over Na2SO4, and then concentrated to give compound 13.2 (20.2 mg, 95% yield). MS: calc'd 439 [(M+H) + ], the measured value is 439[(M+H) + ].

[0256] Step (c): Preparation of tert-butyl N-[1,1-dimethyl-2-oxo-2-[4-[(4R,11aS)-2-(8-cyano-5-quinolyl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-9-yl]piperazin-1-yl]ethyl]carbamate (Compound 13.3)

[0257] To a solution of 5-[(4R,11aS)-4-methyl-9-piperazin-1-yl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile (compound 13.2, 26.1 mg, 48.5 μmol), 2-(tert-butoxycarbonylamino)-2-methyl-propionic acid (CAS: 30992-29-1, Sigma-Aldrich, catalog: 15466, 11.8 mg, 58.2 μmol) and HATU in DMF (5 mL) was added DIEA (18.8 mg, 145.5 μmol). The reaction mixture was stirred at room temperature for 2 hours, then quenched with water and extracted with EA. The organic layer was washed with brine, dried over Na2SO4, and concentrated in vacuo to give compound 13.3 (29.7 mg, 80% yield). MS: calc'd 624[(M+H) + ], the measured value is 624[(M+H) + ].

[0258] Step (d): Preparation of 5-[(4R,11aS)-9-[4-(2-amino-2-methyl-propionyl)piperazin-1-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile (Example 13)

[0259] To a solution of tert-butyl N-[1,1-dimethyl-2-oxo-2-[4-[(4R,11aS)-2-(8-cyano-5-quinolyl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-9-yl]piperazin-1-yl]ethyl]carbamate (compound 13.3, 29.7 mg, 47.7 μmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 30 minutes and then concentrated to give the crude product, which was purified by preparative HPLC to give Example 13 (11.9 mg, 48% yield). MS: calc'd 524 [(M+H) + ], the measured value is 524[(M+H) + ]. 1H NMR (methanol-d4, 400MHz) δ9.00 (dd, 1H, J = 1.6, 4.3Hz), 8.68 (dd, 1H, J = 1.7, 8.6Hz), 8.18 (d, 1H, J = 8.1Hz), 7.67 (dd, 1H, J = 4.2, 8.6Hz) ,7.30(d,1H,J=8.1Hz),7.08(d,1H,J=8.4Hz),6.88(dd,1H,J=2.3,8.3Hz),6.77(d,1H,J=2.1Hz),4.35(d,1H,J=14.8Hz),3.92(br s,4H),3.6-3.7(m,1H),3.49(dd,1H,J=2.1,9.1Hz),3.40(d,1H,J=14.7Hz),3.1-3.2(m,4 H), 3.0-3.1 (m, 1H), 2.8-3.0 (m, 4H), 2.7-2.8 (m, 1H), 1.47 (s, 6H), 1.32 (d, 3H, J = 5.6Hz).

[0260] Example 14

[0261] 5-[(4R,11aS)-4-methyl-9-[4-[(2S)-2-methylpyrrolidine-2-carbonyl]piperazin-1-yl]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0262]

[0263] The title compound was prepared similarly to the preparation of Example 13 by using (2S)-1-tert-butoxycarbonyl-2-methyl-pyrrolidine-2-carboxylic acid (CAS: 103336-06-7, PharmaBlock, catalog: PBN20121551) instead of 2-(tert-butoxycarbonylamino)-2-methyl-propionic acid in step (c). Example 14 was obtained. MS: calc'd 550 [(M+H) + ], the measured value is 550[(M+H) + ]. 1H NMR (methanol-d4, 400MHz) δ9.05 (dd, 1H, J = 1.6, 4.3Hz), 8.73 (dd, 1H, J = 1.7, 8.6Hz), 8.24 (d, 1H, J = 7.9Hz), 7.72 (dd, 1H, J = 4.2, 8.6Hz) ,7.42(d,1H,J=8.1Hz),7.24(d,1H,J=8.6Hz),7.03(dd,1H,J=2.3,8.6Hz),6.89(d,1H,J=2.2Hz),4.96(d,1H,J=15.2Hz),4.39(br d,1H,J=15.2Hz),4.1-4.3(m,1H),3.9-4.0(m,2H),3.7-3.9(m,5H),3.4-3.5(m,2H),3.2-3 .3(m,7H),3.0-3.2(m,1H),2.3-2.5(m,2H),2.0-2.3(m,2H),1.76(s,3H),1.6-1.7(m,3H).

[0264] Example 15

[0265] 5-[(4R,11aS)-9-[(1R,4S)-5-(2-amino-2-methyl-propionyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0266]

[0267] The title compound was prepared similarly to the preparation of Example 13 by using (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (CAS: 113451-59-5, PharmaBlock, catalog: PBN20120579) instead of piperazine-1-carboxylic acid tert-butyl ester in step (a). Example 15 was obtained. MS: calc'd 536 [(M+H) + ], the measured value is 536[(M+H) + ]. 1HNMR (methanol-d4, 400MHz) δ9.07 (dd, 1H, J = 1.6, 4.3Hz), 8.78 (br d,1H,J=8.6Hz),8.26(d,1H,J=7.8Hz),7.6-7.9(m,1H),7.44(d,1H,J=7.7Hz),7.18(d,1H,J=8.7Hz),6.69(dd,1H,J=2.3,8.6Hz),6.55(br s,1H),5.03(s,1H),4.90(br,d,1H,J=14.9Hz),4.6-4.7(m,1H),4.36(d,1H,J=14.9Hz),4.1-4.2( m,1H),3.9-4.1(m,2H),3.4-3.8(m,4H),3.2-3.3(m,3H),3.1-3.2(m,2H),2.0-2.2(m,2H),1.71(br s, 6H), 1.63 (d, 3H, J = 6.5Hz).

[0268] Example 16

[0269] 5-[(4R,11aS)-9-(4-amino-2-oxo-pyrrolidin-1-yl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0270]

[0271] The title compound was synthesized according to the following scheme:

[0272]

[0273] Step (a): Preparation of tert-butyl N-[5-oxo-1-[(4R,11aS)-2-(8-cyano-5-quinolyl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-9-yl]pyrrolidin-3-yl]carbamate (Compound 16.1)

[0274] To a solution of tert-butyl N-(5-oxopyrrolidin-3-yl)carbamate (CAS: 1245648-84-3, BePharm, catalog: BD165019, 60 mg, 299 μmol) in dioxane (5 mL) was added 5-((4R,11aS)-8-bromo-4-methyl-1,3,4,6,11,11a-hexahydro-2H-pyrazino[1,2-b]isoquinoline-2 -yl)quinoline-8-carbonitrile (Intermediate C, 129.6 mg, 299 μmol), Cs2CO3 (136.4 mg, 418.6 μmol) and Pd2(dba)3 (13.7 mg, 14.9 μmol) and Xantphos (CAS: 51364-51-3, Sigma-Aldrich, catalog: 526460, 25.9 mg, 44.7 μmol). The resulting mixture was stirred at 120°C overnight. After cooling to room temperature, the mixture was diluted with water (20 mL) and extracted three times with EA (20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 24 g, 0% to 100% EtOAc in PE) to give compound 16.1 (76.5 mg, 79% yield). MS: calc'd 553 [(M+H) + ], the measured value is 553[(M+H) + ].

[0275] Step (b): Preparation of 5-[(4R,11aS)-9-(4-amino-2-oxo-pyrrolidin-1-yl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile (Example 16)

[0276] To a solution of tert-butyl N-[5-oxo-1-[(4R,11aS)-2-(8-cyano-5-quinolyl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-9-yl]pyrrolidin-3-yl]carboxylate (compound 16.1, 76.5 mg, 138.4 μmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 30 minutes and then concentrated to give the crude product, which was purified by preparative HPLC to give Example 16 (28.3 mg, 45.1% yield). MS: calc'd 453 [(M+H) + ], the measured value is 453[(M+H) + ]. 1H NMR (methanol-d4, 400MHz) δ9.06 (dd, 1H, J = 1.5, 4.3Hz), 8.73 (dd, 1H, J = 1.6, 8.7Hz), 8.25 (d, 1H, J = 7.9Hz), 7.5-7.9 (m, 3H), 7.3-7.5 (m, 2H), 5.07 (br d,1H,J=15.4Hz),4.3-4.6(m,2H),4.1-4.3(m,2H),3.9-4.1(m,3H),3.82(br d,1H,J=12.7Hz), 3.1-3.3(m,5H), 2.69(dd,1H,J=3.3,18.0Hz), 1.64(d,3H,J=6.5Hz).

[0277] Examples 17A and 17B

[0278] 5-[(4R,11aS)-4-methyl-9-[(8aS)-3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile and 5-[(4R,11aS)-4-methyl-9-[(8aR)-3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0279]

[0280] The title compound was prepared according to the following scheme:

[0281]

[0282] Compound 17.1 was prepared similarly to the preparation of Example 16 by using tert-butyl 3-oxo-1,2,5,6,8,8a-hexahydroimidazo[1,5-a]pyrazine-7-carboxylate (CAS: 1246551-25-6, BePharm, catalog: BD286163) instead of tert-butyl N-(5-oxopyrrolidin-3-yl)carbamate in step (a). Compound 17.1 was then decomposed by SFC to give two single isomers: Example 17A (faster elution) and Example 17B (slower elution) on a DAICEL CHIRALPAK AD (10 μm, 250×30 mm) column using 30% methanol (0.1% NH 3 H 2 O) / CO 2 .

[0283] Example 17A MS: Calculated value: 494 [(M+H) +], the measured value is 494[(M+H) + ]. 1 H NMR (methanol-d4, 400MHz) δ8.92 (dd, 1H, J = 1.2, 4.2Hz), 8.61 (dd, 1H, J = 1.3, 8.6Hz), 8.11 (d, 1H, J = 8.1H z),7.60(dd,1H,J=4.3,8.6Hz),7.44(s,2H),7.30(d,1H,J=7.9Hz),7.21(d,1H,J=9.0Hz),4.90(br d,1H,J=15.4Hz),4.33(br d,1H,J=15.4Hz),3.6-4.2(m,8H),3.5-3.6(m,1H),3.44(br d,1H,J=12.3Hz),3.31(br d,1H,J=12.6Hz),3.23(br d,1H,J=3.8Hz),3.1-3.2(m,3H),2.9-3.1(m,3H),1.52(d,3H,J=6.5Hz).

[0284] Example 17B MS: Calculated value: 494 [(M+H) + ], the measured value is 494[(M+H) + ]. 1 H NMR (methanol-d4, 400MHz) δ9.06 (dd, 1H, J = 1.5, 4.2Hz), 8.73 (dd, 1H, J = 1.7, 8.6Hz), 8.25 (d, 1H, J = 7.9Hz) ,7.73(dd,1H,J=4.3,8.6Hz),7.5-7.6(m,2H),7.43(d,1H,J=7.9Hz),7.34(d,1H,J=8.9Hz),5.02(br d,1H,J=15.8Hz),4.44(br d,1H,J=15.4Hz),4.1-4.3(m,6H),3.9-4.1(m,2H),3.7-3.9(m,2H),3.4-3.6(m,2H),3.0-3.3(m,6H),1.63(d,3H,J=6.4Hz).

[0285] Example 18

[0286] 5-[(4R,11aS)-4-methyl-9-(3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0287]

[0288] The title compound was prepared similarly to the preparation of Example 16 by using tert-butyl 3-oxo-2,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridine-5-carboxylate (CAS: 1780976-05-7, PharmaBlock, catalog: PBWBD0104) instead of tert-butyl N-(5-oxopyrrolidin-3-yl)carbamate in step (a). Example 18 was obtained. MS: calc'd 493 [(M+H) + ], the measured value is 493[(M+H) + ]. 1 H NMR (methanol-d4, 400MHz) δ9.06 (d, 1H, J = 4.2Hz), 8.73 (dd, 1H, J = 1.6, 8.6Hz), 8.25 (d, 1H, J = 8.1Hz), 7.6-7.8 (m, 3H), 7.41 (dd, 2H, J = 8.2, 15.8Hz), 5.06 (br d,1H,J=15.9Hz),4.47(br d,1H,J=15.7Hz),4.2-4.3(m,1H),4.12(td,1H,J=4.9,10.1Hz),3.9-4.1(m,2H),3.82(br d,1H,J=13.3Hz),3.5-3.6(m,2H),3.4-3.4(m,1H),3.1-3.3(m,5H),2.8-3.0(m,3H),2.39(br dd,1H,J=1.8,15.2Hz),2.0-2.2(m,1H),1.64(d,3H,J=6.5Hz).

[0289] Example 19

[0290] 5-[(4R,11aS)-4-methyl-9-(1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridin-2-yl)-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile

[0291]

[0292] The title compound was prepared similarly to the preparation of Example 16 by using 1-oxo-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,4-c]pyridine-5-carboxylic acid tert-butyl ester (CAS: 1781135-05-4, PharmaBlock, catalog: PBWBD0105) instead of N-(5-oxopyrrolidin-3-yl)carbamic acid tert-butyl ester in step (a). Example 19 was obtained. MS: calc'd 493 [(M+H) + ], the measured value is 493[(M+H) + ]. 1 H NMR (methanol-d4, 400MHz) δ9.06 (d, 1H, J = 4.0Hz), 8.73 (d, 1H, J = 8.6Hz), 8.25 (d, 1H, J = 7.8Hz), 7.6-7.8 (m, 3H), 7.41 (dd, 2H, J = 8.4, 15.8Hz), 5.05 (br d,1H,J=15.3Hz),4.46(br d,1H,J=15.5Hz),4.1-4.3(m,2H),3.9-4.1(m,2H),3.82(br d,2H,J=13.1Hz),3.58(br dd,2H,J=4.0,10.2Hz),3.0-3.3(m,8H),2.7-2.9(m,1H),2.1-2.2(m,1H),1.64(d,3H,J=6.5Hz).

[0293] Example 20

[0294] To determine the activity of compounds of formula (I) or (Ia) or (Ib) in the HEK293-Blue-hTLR-7 / 8 / 9 cell assay, the following test was performed.

[0295] HEK293-Blue-hTLR-7 Cell Assay:

[0296] The stable HEK293-Blue-hTLR-7 cell line was purchased from InvivoGen (Cat.#: hkb-htlr7, San Diego, California, USA). These cells were originally designed to study human TLR7 stimulation by monitoring NF-κB activation. The SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of the IFN-β minimal promoter fused to five NF-κB and AP-1 binding sites. NF-κB and AP-1 were activated by stimulating HEK-Blue hTLR7 cells with TLR7 ligands to induce SEAP. Therefore, reporter gene expression was reduced by TLR7 antagonists after incubation for 20 hours under ligand stimulation such as R848 (Resiquimod). Using QUANTI-Blue TM The kit (Cat.#: rep-qb1, Invivogen, San Diego, Ca, USA) measures the activity of the SEAP reporter gene in the cell culture supernatant at a wavelength of 640 nm. In the presence of alkaline phosphatase, the detection medium turns purple or blue.

[0297] HEK293-Blue-hTLR7 cells were cultured in a 96-well plate in a volume of 170 μL in Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 g / L glucose, 50 U / mL penicillin, 50 mg / mL streptomycin, 100 mg / mL normocin, 2 mM L-glutamine, and 10% (v / v) heat-inactivated fetal bovine serum. The cells were incubated at a density of 10 cells / mL, and 20 μL of the test compound and 10 μL of 20uM R848 were added to the above DMEM at a final dilution of 1% in the presence of DMSO, and cultured in a CO2 incubator at 37°C for 20 hours. Then 20 μL of the supernatant in each well was incubated with 180 μL of Quanti-blue substrate solution at 37°C for 2 hours, and the spectrophotometer was used to measure the concentration of the supernatant. The signaling pathway that TLR7 activation leads to downstream NF-κB activation is widely accepted, so a similar reporter gene assay was modified to evaluate TLR7 antagonists.

[0298] HEK293-Blue-hTLR-8 Cell Assay:

[0299] The stable HEK293-Blue-hTLR-8 cell line was purchased from InvivoGen (Cat.#: hkb-htlr8, San Diego, California, USA). These cells were originally designed to study human TLR8 stimulation by monitoring NF-κB activation. The SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of the IFN-β minimal promoter fused to five NF-κB and AP-1 binding sites. NF-κB and AP-1 were activated by stimulating HEK-Blue hTLR8 cells with TLR8 ligands to induce SEAP. Therefore, reporter gene expression was reduced by TLR8 antagonists after incubation for 20 hours under ligand stimulation (such as R848). Using QUANTI-Blue TM The kit (Cat.#: rep-qb1, Invivogen, San Diego, Ca, USA) measures the activity of the SEAP reporter gene in the cell culture supernatant at a wavelength of 640 nm. In the presence of alkaline phosphatase, the detection medium turns purple or blue.

[0300] HEK293-Blue-hTLR8 cells were cultured in a 96-well plate in a volume of 170 μL in Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 g / L glucose, 50 U / mL penicillin, 50 mg / mL streptomycin, 100 mg / mL normocin, 2 mM L-glutamine, and 10% (v / v) heat-inactivated fetal bovine serum. The cells were incubated at a density of 10 cells / mL, and 20 μL of the test compound and 10 μL of 60uM R848 were added to the above DMEM at a final dilution of 1% in the presence of DMSO, and cultured in a CO2 incubator at 37°C for 20 hours. Then 20 μL of the supernatant in each well was incubated with 180 μL of Quanti-blue substrate solution at 37°C for 2 hours, and the spectrophotometer was used to measure the concentration of the supernatant. The signaling pathway that TLR8 activation leads to downstream NF-κB activation is widely accepted, so a similar reporter gene assay was modified to evaluate TLR8 antagonists.

[0301] HEK293-Blue-hTLR-9 cell assay:

[0302] The stable HEK293-Blue-hTLR-9 cell line was purchased from InvivoGen (Cat.#:hkb-htlr9, San Diego, California, USA). These cells were originally designed to study human TLR9 stimulation by monitoring NF-κB activation. The SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of the IFN-β minimal promoter fused to five NF-κB and AP-1 binding sites. NF-κB and AP-1 were activated by stimulating HEK-Blue hTLR9 cells with TLR9 ligands to induce SEAP. Therefore, reporter gene expression was reduced by TLR9 antagonists by incubation for 20 hours under stimulation with ligands such as ODN2006 (Cat.#:tlrl-2006-1, Invivogen, San Diego, California, USA). Using QUANTI-Blue TM The kit (Cat.#: rep-qb1, Invivogen, San Diego, California, USA) measures the activity of the SEAP reporter gene in the cell culture supernatant at a wavelength of 640 nm. In the presence of alkaline phosphatase, the detection medium turns purple or blue.

[0303] HEK293-Blue-hTLR9 cells Cells / mL were incubated in a 96-well plate in Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 g / L glucose, 50 U / mL penicillin, 50 mg / mL streptomycin, 100 mg / mL Normocin, 2 mM L-glutamine, 10% (v / v) heat-inactivated fetal bovine serum at a density of 170 μL, wherein 20 μL of the test compound and 10 μL of 20 uMODN2006 were added to the above DMEM solution in a serial dilution in the presence of 1% final DMSO, and incubated in a CO2 incubator at 37°C for 20 hours. Then 20 μL of the supernatant in each well was incubated with 180 μL Quanti-blue substrate solution at 37°C for 2 hours and the spectrophotometer was used to measure the concentration of the supernatant. The absorbance was read at 400 nm. The signaling pathway by which TLR9 activation leads to downstream NF-κB activation is widely accepted, so a similar reporter gene assay was modified to evaluate TLR9 antagonists.

[0304] The compounds of formula (I) have TLR7 and / or TLR8 inhibitory activity (IC 50 In addition, most compounds also have TLR9 inhibitory activity of <0.3 μM. Table 1 shows the activity data of the compounds of the present invention.

[0305] Table 1: Activity of compounds of the invention in HEK293-Blue-hTLR-7 / 8 / 9 cell assay

[0306]

[0307] Example 21

[0308] Human microsomal stability assay

[0309] Human liver microsomes (Catalog No.: 452117, Corning, USA) were pre-incubated with the test compound in 100mM potassium phosphate buffer (pH 7.4) at 37°C for 10 minutes. The reaction was initiated by adding an NADPH regeneration system. The final incubation mixture contained 1 μM test compound, 0.5mg / mL liver microsomal protein, 1mM MgCl2, 1mM NADP, 1 unit / mL isocitrate dehydrogenase and 6mM isocitrate in 100mM potassium phosphate buffer (pH 7.4). After incubation at 37°C for 0, 3, 6, 9, 15 and 30 minutes, 300 μL cold ACN (including internal standard) was added to the 100 μL incubation mixture to terminate the reaction. After precipitation and centrifugation, 100uL supernatant was taken out and 300uL water was added. The amount of the compound remaining in the sample was determined by LC-MS / MS. Controls without NADPH regeneration system at zero and 30 minutes were also prepared and analyzed. Results were categorized as: low (<7.0 mL / min / kg), medium (7.0-16.2 mL / min / kg), and high (16.2-23.2 mL / min / kg). The test results are summarized in Table 2.

[0310] Table 2: Human microsomal stability results

[0311]

[0312] Example 22

[0313] hERG channel inhibition assay

[0314] The hERG channel inhibition assay is a highly sensitive measurement that identifies compounds that exhibit hERG inhibition associated with in vivo cardiotoxicity. + The channel was cloned into human and stably expressed in CHO (Chinese Hamster Ovary) cell line. hERG Cells were used for patch clamp (voltage clamp, whole cell) experiments. Voltage mode stimulation of cells activated hERG channels and conducted I KhERG Current (fast delayed outward rectifier potassium current of hERG channels). After the cells were stable for several minutes, I was recorded at a stimulation frequency of 0.1 Hz (6 bpm). KhERGThe amplitude and kinetics of the oscillations were then measured. Thereafter, the test compound was added to the formulation at increasing concentrations. For each concentration, an attempt was made to reach a steady-state effect, which was usually achieved within 3-10 minutes, at which time the next highest concentration was applied. The I KhERG The amplitude and kinetics of the oscillations were measured and compared with the control values ​​(considered as 100%). (Reference: Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, PalethorpeS, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG.2003; Relationships between preclinical cardiac electrophysiology, clinical QTinterval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drugdevelopment.Cardiovasc.Res.58:32-45,Sanguinetti MC,Tristani-Firouzi M.2006;hERG potassium channels and cardiac arrhythmia.Nature 440:463-469,Webster R,Leishman D,Walker D.2002;Towards a drug concentration effect relationship for QT prolongation and torsades de points.Curr.Opin.Drug Discov. Devel. 5:116-26). The results of hERG are given in Table 3.

[0315] Table 3: hERG results

[0316]

Claims

1. A compound of formula (I), in R 1 for Where R 4 is cyano; R 5 is H or deuterium; R 2 C 1-6 alkyl; R 3 For (amino C 1-6 alkylcarbonyl)-2,5-diazabicyclo[2.2.1]heptyl; (amino C 1-6 Alkylcarbonyl)piperazinyl; (C 1-6 Alkoxypyrrolidinyl)amino; (C 1-6 Alkyl)2AminoC 1-6 Alkoxy; (C 1-6 (alkylpyrrolidinylcarbonyl)piperazinyl; (halopyrrolidinyl)amino; (hydroxypyrrolidinyl)C 1-6 Alkylamino; (morpholinyl)C 1-6 Alkylamino; 1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl; 3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridinyl; amino(C 1-6 alkyloxy)pyrrolidinyl; amino-1,4-oxazepanyl; aminohalogenated pyrrolidinyl; aminooxopyrrolidinyl or azetidinyl C 1-6 Alkoxy; or a pharmaceutically acceptable salt thereof.

2. A compound of formula (Ia), in R 1 for Where R 4 is cyano, R 5 is H or deuterium; R 2 C 1-6 alkyl; a) R 3a For (C 1-6 Alkyl)2AminoC 1-6 Alkoxy; (halopyrrolidinyl)amino; (hydroxypyrrolidinyl)C 1-6 Alkylamino; (morpholinyl)C 1-6 Alkylamino or amino-1,4-oxazepanyl; R 3b is H; or b) R 3a is H; R 3b For (amino C 1-6 alkylcarbonyl)-2,5-diazabicyclo[2.2.1]heptyl; (amino C 1-6 Alkylcarbonyl)piperazinyl; (C 1-6 Alkoxypyrrolidinyl)amino; (C 1-6 Alkyl)2AminoC 1-6 Alkoxy; (C 1-6 alkylpyrrolidinylcarbonyl)piperazinyl; (halopyrrolidinyl)amino; 1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl; 3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridinyl; amino(C 1-6 alkyloxy)pyrrolidinyl; aminohalopyrrolidinyl; aminooxopyrrolidinyl or azetidinyl C 1-6 Alkoxy; or a pharmaceutically acceptable salt thereof.

3. A compound of formula (Ib), in R 1 for Where R 4 is cyano, R 5 is H or deuterium; R 2 C 1-6 alkyl; a) R 3a For (C 1-6 Alkyl)2AminoC 1-6 Alkoxy; (halopyrrolidinyl)amino; (hydroxypyrrolidinyl)C 1-6 Alkylamino; (morpholinyl)C 1-6 Alkylamino or amino-1,4-oxazepanyl; R 3b is H; or b) R 3a is H; R 3b For (amino C 1-6 alkylcarbonyl)-2,5-diazabicyclo[2.2.1]heptyl; (amino C 1-6 Alkylcarbonyl)piperazinyl; (C 1-6 Alkoxypyrrolidinyl)amino; (C 1-6 Alkyl)2AminoC 1-6 Alkoxy; (C 1-6 alkylpyrrolidinylcarbonyl)piperazinyl; (halopyrrolidinyl)amino; 1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl; 3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridinyl; amino(C 1-6 alkyloxy)pyrrolidinyl; aminohalopyrrolidinyl; aminooxopyrrolidinyl or azetidinyl C 1-6 Alkoxy; or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 2 or 3, wherein R 1 for Where R 4 is cyano, R 5 is H or deuterium; R 2 C 1-6 alkyl; R 3a is H; R 3b For (amino C 1-6 alkylcarbonyl)-2,5-diazabicyclo[2.2.1]heptyl; (amino C 1-6 Alkylcarbonyl)piperazinyl; (C 1-6 Alkoxypyrrolidinyl)amino; (C 1-6 Alkyl)2AminoC 1-6 Alkoxy; (C 1-6 (alkylpyrrolidinylcarbonyl)piperazinyl; (halopyrrolidinyl)amino; 1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl; 3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridinyl; amino(C 1-6 alkyloxy)pyrrolidinyl; aminohalopyrrolidinyl; aminooxopyrrolidinyl or azetidinyl C 1-6 Alkoxy; or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 4, wherein R 2 It is methyl.

6. The compound according to claim 4, wherein R 3b is (2-amino-2-methyl-propionyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl; (2-amino-2-methyl-propionyl)piperazin-1-yl; (2-methylpyrrolidine-2-carbonyl)piperazin-1-yl; (4-fluoropyrrolidin-3-yl)amino; (4-methoxypyrrolidin-3-yl)amino; (azetidin-2-yl)methoxy; 1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridin-2-yl; 2-(dimethylamino)ethoxy; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl; 3-amino-4-fluoro-pyrrolidin-1-yl; 3-amino-4-methoxy-pyrrolidin-1-yl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl; 3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl or 4-amino-2-oxo-pyrrolidin-1-yl.

7. The compound according to claim 4, wherein R 3b For (C 1-6 alkylpyrrolidinylcarbonyl)piperazinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl or azetidinyl C 1-6 Alkoxy.

8. The compound according to claim 7, wherein R 3b It is (2-methylpyrrolidine-2-carbonyl)piperazin-1-yl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl or (azetidin-2-yl)methoxy.

9. The compound according to claim 2 or 3, wherein R 1 for Where R 4 is cyano, R 5 is H or deuterium; R 2 C 1-6 alkyl; R 3a is H; R 3b For (C 1-6 alkylpyrrolidinylcarbonyl)piperazinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl or azetidinyl C 1-6 Alkoxy; or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 9, wherein R 1 for Where R 4 is cyano, R 5 is H or deuterium; R 2 is methyl; R 3a is H; R 3b is (2-methylpyrrolidine-2-carbonyl)piperazin-1-yl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl; 3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl or (azetidin-2-yl)methoxy; or a pharmaceutically acceptable salt thereof.

11. A compound selected from: 5-[(4R,11aS)-8-(6-amino-1,4-oxazepan-4-yl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-8-[2-[(3S)-3-hydroxypyrrolidin-1-yl]ethylamino]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-4-methyl-8-[[(2R)-morpholin-2-yl]methylamino]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-8-[[(3S,4R)-4-fluoropyrrolidin-3-yl]amino]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-8-[2-(dimethylamino)ethoxy]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-4-methyl-9-[[(3R,4S)-4-fluoropyrrolidin-3-yl]amino]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-9-[[(3R,4S)-4-methoxypyrrolidin-3-yl]amino]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-9-[(3S,4R)-3-amino-4-fluoro-pyrrolidin-1-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-9-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-9-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-9-[2-(dimethylamino)ethoxy]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-9-[[(2S)-azetidin-2-yl]methoxy]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-4-methyl-9-[[(3R,4S)-4-fluoropyrrolidin-3-yl]amino]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-4-methyl-9-[4-[(2S)-2-methylpyrrolidine-2-carbonyl]piperazin-1-yl]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-9-[(1S,4S)-5-(2-amino-2-methyl-propionyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-9-(4-amino-2-oxo-pyrrolidin-1-yl)-4-methyl-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-4-methyl-9-[(8aS)-3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-4-methyl-9-[(8aR)-3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-2-yl]-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; 5-[(4R,11aS)-4-methyl-9-(3-oxo-3a,4,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; and 5-[(4R,11aS)-4-methyl-9-(1-oxo-3a,4,5,6,7,7a-hexahydro-3H-pyrrolo[3,4-c]pyridin-2-yl)-1,3,4,6,11,11a-hexahydropyrazino[1,2-b]isoquinolin-2-yl]quinoline-8-carbonitrile; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 and a therapeutically inert carrier.

13. Use of a compound according to any one of claims 1 to 11 for the preparation of a medicament for the treatment or prevention of systemic lupus erythematosus or lupus nephritis.

14. Use of a compound according to any one of claims 1 to 11 for the preparation of a medicament for a TLR7, TLR8 and TLR9 antagonist.